Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc

This study is testing a personalized cell therapy (CAR-T cells) for people with brain cancer called glioblastoma (GBM) that has come back after initial treatment. The therapy uses the patient's own immune cells, engineered to target a protein called B7-H3 found on GBM tumor cells. **You may be eligible if...** - You have been diagnosed with recurrent or treatment-resistant glioblastoma - You have previously had surgery or biopsy and received radiation with chemotherapy - You have not been treated with anti-angiogenic drugs like bevacizumab - You have not previously received CAR-T therapy for glioblastoma - You are well enough to function independently (Karnofsky score above 60%) - You are able to have an MRI scan **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have HIV, hepatitis B, or hepatitis C - You have another active cancer that may interfere with this study - Your brain tumor has spread to the brainstem, cerebellum, or spinal cord - You have metal implants or a pacemaker that prevents MRI - You have previously had carmustine wafers implanted in your brain Talk to your doctor to see if this trial is right for you.